As expected, PAH-PASMCs had a significantly greater proliferation rate (as assessed by Ki67 labeling) and were more resistant to apoptosis (as assessed by Annexin V assay) when compared to control PASMCs. Here, ANXA5 is linked to pulmonary arterial hypertension.